India’s progress and sustenance as a leading economic power is leveraged on meeting some of the basic determinants of health-related SDGs (Sustainable Development Goals) and reducing disparities in access to quality care. Start-ups in India have been at the forefront of bringing innovation to healthcare. They increase the capacity and reach of healthcare providers and empower patients and their caregivers to understand and participate in their care plans.
However, to ensure that these start-ups reach the people that need them and evolve into successful businesses to scale in various geographies, it is essential that they find an enabling ecosystem to help them accelerate their lab-to-market journey. Support for clinical trials and validation, regulatory approvals, and defining the right go-to-market strategy can greatly improve the adoption for these innovations.
To support this journey, Pfizer India, and Social Alpha have joined hands to anchor the Pfizer INDovation Program to help accelerate the journey of start-ups into the market through customised support and by fostering relevant cross-industry collaborations.
The Pfizer INDovation Program brings together various stakeholders including Social Alpha, the Atal Innovation Mission, NITI Aayog, Foundation for Innovation and Technology Transfer (FITT), IIT-Delhi, Agnii, amongst others on the same platform to unlock greater reach of care, and effectiveness in our healthcare system.
The initiative aims to guide high-quality start-ups and accelerate their journey through product engineering and development services, clinical validation support, regulatory advisory, and market access opportunities through grant support and catalytic cross-industrial collaborations.
The program provides start-ups access to grant funding, incubation support, marketing and branding support, business advisory support, and opportunities to secure follow-on funding.